Psychiatric Comorbidity Increases Risk for Schizophrenia With ADHD
By Lori Solomon HealthDay Reporter
THURSDAY, Nov. 30, 2023 -- The presence of psychiatric comorbidity in young patients with attention-deficit/hyperactivity disorder (ADHD) is associated with a higher risk for being diagnosed with schizophrenia, according to a study published online Nov. 30 in JAMA Network Open.
Soo Min Jeon, Pharm.D., Ph.D., from Jeju National University in South Korea, and colleagues assessed the risk for being diagnosed with schizophrenia among children and adolescents with ADHD. The analysis included 211,705 children and adolescents (ages 5 to 19 years) who received an ADHD diagnosis in 2010 through 2018.
The researchers found that patients with psychiatric comorbidity had a significantly higher risk for being diagnosed with schizophrenia than those without (adjusted hazard ratio, 2.14) in a dose-response manner. Several individual psychiatric disorders were associated with incident schizophrenia, including autism spectrum disorder, intellectual disability, tic disorder, depression, and bipolar disorder. Three-fourths of patients (73.8 percent) without psychiatric comorbidities experienced the emergence of other psychiatric disorders before developing schizophrenia.
"These findings highlighted the significance of carefully monitoring psychiatric comorbidities in patients with ADHD to effectively mitigate the burden of schizophrenia," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted November 2023
Read this next
SNP rs13194504 AA Genotype Linked to Severity of Tardive Dyskinesia
TUESDAY, June 25, 2024 -- For patients with schizophrenia, the single-nucleotide polymorphism (SNP) rs13194504 AA genotype is associated with reduced severity of tardive...
ADHD Meds May Help Control Opioid Use Disorder in Pregnancy
TUESDAY, June 25, 2024 -- Psychostimulants may help opioid use disorder (OUD) outcomes in pregnant women, according to a study published online June 11 in Nature Mental...
FDA Approves First Liquid, Nonstimulant ADHD Treatment, Onyda XR
MONDAY, June 3, 2024 -- The U.S. Food and Drug Administration has approved once-daily Onyda XR (clonidine hydrochloride) as the first liquid, nonstimulant treatment for...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.